Artwork

Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

New hope in the quest for a novel add-on therapy for uncontrolled hypertension

9:58
 
Share
 

Manage episode 410460349 series 2680968
Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Elevated blood pressure, called hypertension, is the leading risk factor for death and disability worldwide. However, many patients find it is not possible to achieve a healthy blood pressure despite taking three or more blood-pressure-lowering medications; a condition referred to as resistant hypertension.
Professor Markus Schlaich at The University of Western Australia, together with colleagues from other centres worldwide, has conducted the PRECISION clinical trial to assess whether the novel drug aprocitentan could improve blood pressure control in patients with resistant hypertension.
Read the original research: doi.org/10.1007/s11906-023-01259-z
Read more in Research Features

  continue reading

372 episodes

Artwork
iconShare
 
Manage episode 410460349 series 2680968
Content provided by ResearchPod. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ResearchPod or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Elevated blood pressure, called hypertension, is the leading risk factor for death and disability worldwide. However, many patients find it is not possible to achieve a healthy blood pressure despite taking three or more blood-pressure-lowering medications; a condition referred to as resistant hypertension.
Professor Markus Schlaich at The University of Western Australia, together with colleagues from other centres worldwide, has conducted the PRECISION clinical trial to assess whether the novel drug aprocitentan could improve blood pressure control in patients with resistant hypertension.
Read the original research: doi.org/10.1007/s11906-023-01259-z
Read more in Research Features

  continue reading

372 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide